Combination statin-fibrate therapy: Safety aspects

Diabetes, Obesity and Metabolism

Volumn 11, Issue 2, 2009, Pages 89-94

  Franssen, R ^a   Vergeer, M ^a   Stroes, E S G ^a   Kastelein, J J P ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Combination therapy; Fenofibrate; Fibrates; Metabolic syndrome; Myopathy; Type 2 diabetes

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 2C9; DRUG METABOLIZING ENZYME; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; GLUCURONIDATION; HUMAN; HYPERCHOLESTEROLEMIA; METABOLIC SYNDROME X; MONOTHERAPY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 58149350262     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00917.x     Document Type: Review

References (49)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
2. Grundy SM, Cleeman JI, Merz NB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
3. Ryden L, Standl E, Bartnik M et al. on behalf of the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes, and cardiovascular disease: Executive summary. Eur Heart J 2007;28: 88-136
4. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006; 29: S4-S42
5. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126
6. Smith SC, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006; 113: 2363-2372
7. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options. Am J Cardiol 2005; 96 (Suppl.): 53E-59E
8. St-Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553-559
9. Pedersen TR, Faergeman O, Kastelein JJP et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: A randomized controlled trial. JAMA 2005; 294: 2437-2445.
10. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. The Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-1226.
11. Ravnskov U, Rosch PJ, Sutter MC, Houston MC. Should we lower cholesterol as much as possible? BMJ 2006; 332: 1330-1332.
12. Birjmohun RS, Hutten BA, Kastelein JJP et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-197.
13. Chapman MJ. Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171: 1-13.
14. Feher MD, Caslake M, Foxton J et al. Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999; 15: 395-399.
15. Vakkilainen J, Steiner G, Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The Diabetes Atherosclerosis Study (DAIS). Circulation 2003; 107: 1733-1737.
16. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007; 154: 943-953.
17. Koskinen P, Mantarri M, Manninen V et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.
18. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162: 2597
19. Diabetes Atherosclerosis Intervention Study investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910
20. Keech A, Simes RJ, Barter P et al. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366: 1849-1861.
21. Tenenbaum A, Fisman EZ, Boyko V et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006; 166: 737-741.
22. Cheng AY, Leiter LA. PPAR-alpha: Therapeutic role in diabetes-related cardiovascular disease. Diabetes Obes Metab 2007; doi: 10.1111/ j.1463-1326.2007.00747.x
23. Athyros VG, Papageorgiou A, Athyrou VV et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25: 1198-1202.
24. Grundy SM, Vega GL, Yuan Z et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95: 462-468.
25. Durrington PN, Tuomilehto J, Hamann A et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidemia. Diabetes Res Clin Pract 2004; 64: 137-151.
26. Farnier M. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003; 92: 794-797.
27. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00000620. Accessed 20 May 2007.
28. Ballantyne CM, Corsini A, Davidson MH et al. Risk of myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-564.
29. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116: 408-416.
30. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004; 94: 935-938.
31. Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalised rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-2590.
32. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-122.
33. Neil A, Wheeler F, Cull C et al. Combination statin and fibrate therapy in type 2 diabetes: Results from the Lipids in Diabetes Study. Diabetes 2003; 52 (Suppl.): A74 [abstract]
34. Prueksaritanont T, Tang C, Qui Y et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1290-1297
35. Prueksaritanont T, Subramanian R, Fang X et al. Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505-512.
36. Wen X, Wang JS, Backman JT et al. Gemfibrozil is a potent inhibitor of human cytochrome P450 2CP. Drug Metab Dispos 2001; 29: 1359-1361.
37. Backman JT, Kyrklund C, Kivisto KT et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-129.
38. Bergman AJ, Murphy G, Burke J et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44: 1054-1062.
39. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538-544.
40. Gustavson LE, Schweitzer SM, Koehne-Voss S et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3_-hydroxy isomeric metabolite. J Clin Pharmacol 2005; 45: 947-953.
41. Pan WJ, Gustavson LE, Achari R et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000; 40: 316-323.
42. Schnek DW, Birmingham BK, Zalikowski JA et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75: 455-463.
43. Martin PD, Dane AL, Schneck DW et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003; 25: 459-471.
44. Spence JD, Munoz CE, Hendricks L et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75: 455-463.
45. Kyrklund C, Backman JT, Kivisto KT et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340-345.
46. Backman JT, Kyrklund C, Neuvonen M et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72: 685-691.
47. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005; 96(Suppl.): 44K-49K.
48. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interations. Expert Opin Drug Saf 2006; 5: 145-156.
49. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99 (Suppl.): 3C-18C.